Sonnet BioTherapeutics Holdings, Inc. (SONN)
NASDAQ: SONN · Real-Time Price · USD
3.950
+0.960 (32.11%)
At close: Aug 13, 2025, 4:00 PM
3.480
-0.470 (-11.90%)
Pre-market: Aug 14, 2025, 9:20 AM EDT
SONN Employees
Sonnet BioTherapeutics Holdings had 13 employees as of September 30, 2024. The number of employees increased by 1 or 8.33% compared to the previous year.
Employees
13
Change (1Y)
1
Growth (1Y)
8.33%
Revenue / Employee
$76,923
Profits / Employee
-$1,042,787
Market Cap
24.74M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SONN News
- 3 days ago - Sonnet Releases Virtual Investor "What This Means" Segment - GlobeNewsWire
- 10 days ago - Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer - GlobeNewsWire
- 4 weeks ago - Why Is Sonnet BioTherapeutics Stock Trading Higher On Monday? - Benzinga
- 4 weeks ago - Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy - GlobeNewsWire
- 3 months ago - Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit - GlobeNewsWire
- 4 months ago - Sonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose - GlobeNewsWire
- 4 months ago - Sonnet Announces Release of Corporate Update Video - GlobeNewsWire
- 4 months ago - Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D. - GlobeNewsWire